Fund Holdings — Lynx1 Capital Management LP

Total Portfolio Value:
$646.09M
Total Bought:
$30.64M
Total Sold:
$144.92M
Net Transaction:
-$114.27M
Notable People:
Weston Agnew Nichols
Securities
▲▼
SharesValue
Q2 2026
▲▼
Q3 2026
▲▼
Change
▲▼
Q2 2026
▲▼
Q3 2026
▲▼
Weight (%)
▲▼
Change
▲▼
GH Research PLC(GHRS)13,263,28813,263,2880$356.52M$311.42M48.20%-$45.10M
Cullinan Therapeutics Inc8,963,5008,963,5000$163.23M$137.59M21.30%-$25.64M
Stoke Therapeutics, Inc.(STOK)4,038,4043,896,169-142,235$132.14M$101.30M15.68%-$30.84M
C4 Therapeutics Inc7,326,6917,530,915+204,224$34.22M$25.08M3.88%-$9.14M
Precision Biosciences Inc950,4662,758,215+1,807,749$7.47M$17.27M2.67%+$9.80M
Agios Pharmaceuticals, Inc.(AGIO)3,408,937472,606-2,936,331$126.51M$15.71M2.43%-$110.79M
Korro Bio Inc1,538,2961,544,980+6,684$20.27M$15.31M2.37%-$4.96M
Neuphoria Therapeutics Inc875,328875,3280$3.83M$3.12M0.48%-$709.0K
Passage Bio Inc673,759673,7590$3.29M$3.03M0.47%-$256.0K
Proqr Thrapeutics N VSHS EURO
SHS EURO
521,4131,562,093+1,040,680$969.8K$2.59M0.40%+$1.62M
Tscan Therapeutics Inc8,019,1488,019,1480$7.86M$2.52M0.39%-$5.34M
Kazia Therapeutics LtdADS0225,800+225,800$0$2.17M0.34%+$2.17M
Pliant Therapeutics Inc1,798,0701,798,0700$2.05M$1.94M0.30%-$107.9K
Entrada Therapeutics Inc178,606278,606+100,000$1.31M$1.77M0.27%+$454.6K
Surrozen Inc020,000+20,000$0$643.6K0.10%+$643.6K
Immatics N.V.SHS(IMTX)23,23671,263+48,027$235.4K$625.7K0.10%+$390.3K
Werewolf Therapeutics Inc657,786657,7860$236.7K$606.7K0.09%+$369.9K
Yarrow Bioscience Inc022,000+22,000$0$495.4K0.08%+$495.4K
Xencor, Inc.(XNCR)18,19418,1940$292.9K$453.9K0.07%+$161.0K
Immunocore Holdings plcADS(IMCR)014,300+14,300$0$433.1K0.07%+$433.1K
Dyne Therapeutics, Inc.(DYN)025,000+25,000$0$402.8K0.06%+$402.8K
Traws Pharma Inc559,470559,4700$471.8K$332.2K0.05%-$139.6K
Denali Therapeutics Inc.(DNLI)11,65811,6580$299.8K$241.0K0.04%-$58.9K
Absci Corporation21,24521,2450$246.2K$228.8K0.04%-$17.4K
Foghorn Therapeutics Inc61,58861,5880$300.5K$219.9K0.03%-$80.7K
Avalo Therapeutics Inc10,10010,1000$186.6K$154.8K0.02%-$31.8K
Prime Medicine, Inc.(PRME)045,000+45,000$0$137.5K0.02%+$137.5K
Bolt Biotherapeutics Inc30,80030,8000$118.6K$113.3K0.02%-$5.2K
Eupraxia Pharmaceuticals Inc10,00010,0000$66.1K$91.0K0.01%+$24.9K
Nuvation Bio Inc.CL A(NUVB)16,02916,0290$91.0K$89.8K0.01%-$1.3K
Inhibikase Therapeutics Inc20,00020,0000$40.6K$1.2K0.00%-$39.4K
CG Oncology, Inc.(CGON)31,3910-31,391$2.23M$0—-$2.23M
Yarrow Bioscience Inc(YARW)1,628,7000-1,628,700$1.06M$0—-$1.06M
Page 1 of 1
Lynx1 Capital Management LP — 13F Holdings — Q3 2026 | TickerTrail